Unknown

Dataset Information

0

Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019.


ABSTRACT: Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.

SUBMITTER: Titanji BK 

PROVIDER: S-EPMC7337637 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7190990 | biostudies-literature
| S-EPMC9384601 | biostudies-literature
| S-EPMC7331556 | biostudies-literature
| S-EPMC8313076 | biostudies-literature
| S-EPMC8711791 | biostudies-literature
| S-EPMC7797739 | biostudies-literature
| S-EPMC10636462 | biostudies-literature
| S-EPMC7453989 | biostudies-literature
| S-EPMC7128660 | biostudies-literature
| S-EPMC7523477 | biostudies-literature